• My Basket 0

    Badrilla Default welcome msg!

    Calcineurin

    Calcineurin

    Exceptional, fully validated antibodies to Calcineurin Phospho Serine-197 (anti-CN PS-197). Lyophilised with stabilizer for economical and environmentally friendly shipment and storage.

    Calcineurin (CN) is a protein phosphatase also known as protein phosphatase 3, PPP3CA, and calcium-dependent serine-threonine phosphatase, and formerly known as protein phosphatase 2B (PP2B).[1] It activates the T cells of the immune system and can be blocked by drugs. Calcineurin activates NFATc (Nuclear Factor of Activated T cell, cytoplasmic), a transcription factor, by dephosphorylating it. The activated NFATc is then translocated into the nucleus, where it upregulates the expression of interleukin 2 (IL-2), which, in turn, stimulates the growth and differentiation of T cell response. Calcineurin is the target of a class of drugs called calcineurin inhibitors, which includes cyclosporine, pimecrolimus and tacrolimus.

    1 Item(s)

    1. Calcineurin (pSer197) pAb IgG

      $325.00
      Product code: A010-80AP

      Lyophilised rabbit polyclonal antibody (IgG) preparation conatining antibodies specific for Ser-197 phosphorylated forms Calcineurin.

      • Suitable Western blot (1:200 dilution)
      • Lyophilised total IgG
      • Recognises calcineurin in mouse/rat/human/monkey/other, when phosphorylated on Ser-197
      • Unit size: 100 μl
      Learn More

    1 Item(s)

    Shop By

    Currently Shopping by:

    1. Product type: Antibody Remove This Item
    Target
    1. Calcineurin (1)
    Phosphorylation site
    1. pSer197 (1)
    Compare

    You have no items to compare.

    Contact Us

    Badrilla Ltd.

    15 Queen Square

    Leeds LS2 8AJ

    United Kingdom

     

    +44 (0)7801 730618

     

    info@badrilla.com

    Useful Links

    .

    DISCLAIMER: Products for research use only (RUO) and are not intended for diagnostic or therapeutic use.

    Badrilla Newsletters

    Sign up for Badrilla newsletters today and receive twice-monthly informative emails relating to cardiovascular research.
    Badrilla enewsletter sign up